Goserelin acetate (ICI-118630 acetate) 是一种促性腺激素释放激素 (GnRH/LHRH) 十肽类似物,能作为GnRH激动剂。Goserelin acetate 可用于乳腺癌、上皮性卵巢癌和前列腺癌的研究。
生物活性 | Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as aGnRHagonist. Goserelin acetate can be used for the research of breastcancer, epithelial ovariancancerand prostatecancer[1][2]. |
IC50& Target | |
体外研究 (In Vitro) | Goserelin (1 nM-1 mM; 48-72 hours) promotes EOC cell apoptosis[1]. Goserelin (100 μM; 24-72 hours) regulates the expression of human apoptosis-related genes in SKOV3-ip cells[1]. Goserelin (100 μM; 24-72 hours) promotes EOC cell apoptosis by upregulating FOXO1 through the PI3K/AKT signaling pathway[1].
Apoptosis Analysis[1] Cell Line: | SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell lines) | Concentration: | 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM | Incubation Time: | 48 hours, 72 hours | Result: | Significantly increased the total apoptosis rate of SKOV3-ip, SKOV3 and A2780 cells. |
Western Blot Analysis[1] Cell Line: | SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell lines) | Concentration: | 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM | Incubation Time: | 48 hours, 72 hours | Result: | The expression of cleaved-caspase-3 and cleaved-PARP were observably increased at 100 μM. |
RT-PCR[1] Cell Line: | SKOV3-ip cells | Concentration: | 100 μM | Incubation Time: | 24 hours, 48 hours, 72 hours | Result: | Expression of human apoptosis-related genes regulated |
|
体内研究 (In Vivo) | Goserelin (100 μg; s.c.; daily; for 19 days) significantly increases the proportion of apoptotic cells in the subcutaneous xenograft tumors[1].
Animal Model: | Five-week-old specific-pathogen free (SPF) female nude mice (18-20 g), subcutaneous xenograft tumor model[1] | Dosage: | 100 μg/mice | Administration: | Subcutaneous injection, daily, for 19 days | Result: | Significantly increased the proportion of apoptotic cells in the subcutaneous xenograft tumors |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Sealed storage, away from moisture Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 100 mg/mL(75.22 mM;Need ultrasonic) DMSO : ≥ 28 mg/mL(21.06 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 0.7522 mL | 3.7609 mL | 7.5219 mL | 5 mM | 0.1504 mL | 0.7522 mL | 1.5044 mL | 10 mM | 0.0752 mL | 0.3761 mL | 0.7522 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 50 mg/mL (37.61 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (1.56 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (1.56 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (1.56 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (1.56 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: 2.08 mg/mL (1.56 mM); Clear solution; Need warming
此方案可获得 2.08 mg/mL (1.56 mM) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|